Summary by Futu AI
On October 24, 2024, 180 Life Sciences Corp. announced the appointment of Jay Goodman to its Board of Directors, effective immediately. Goodman, with over a decade of experience in the SaaS and iGaming industries, has been appointed as a Class I director and will serve until the 2025 Annual Meeting of Stockholders. The Board has determined that Goodman is independent according to Nasdaq rules and will serve on the Nominating and Corporate Governance Committee, Audit Committee, and as Chairman of the Compensation Committee. Goodman's appointment follows the mutual termination of Blair Jordan's Offer Letter due to his new role as Interim CEO. Goodman's compensation includes an annual retainer fee of $50,000 and an additional $15,000 for his role as Chairperson of the Compensation...Show More